# Recombinant Human Erythropoietin

## EPO inj 1 IU (H/D OPD Only)

##### 

| 標題       | 說明                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 藥品代碼   | IEPO1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 適應症     | Treatment of anemia associated with chronic renal failure in pediatric & adult patients on hemodialysis & adult patients on peritoneal dialysis. Treatment of severe anemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. Treatment of anaemia in adult cancer patients receiving chemotherapy & to maintain Hb levels in adult cancer patients at risk of developing anemia during chemotherapy                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 用法用量   | Chronic renal failure Adult patients Correction phase: 50 iu/kg 3 times/week IV. When necessary, dose adjustments should be made in increments of 25 iu/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (10-12 g/dL ) is achieved. Maintenance phase: Individualised dose. The recommended total weekly dose is 75-300 iu/kg. Pediatric patients Correction phase: 50 iu/kg 3 times/week IV. When necessary, dose adjustments should be made in increments of 25 iu/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (9.5-11 g/dL) is achieved. Maintenance phase: Generally, children < 30 kg require higher maintenance doses than children > 30 kg & adults Cancer patients Initially 150 iu/kg 3 times/week. If after 4 weeks the Hb increase is < 1 g/dL the dose should be increased to 300 iu/kg for an additional 4 weeks. |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 禁忌       | Patients who develop antibody-mediated Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin should not receive Eprex or any other erythropoietin . Uncontrolled hypertension. Known hypersensitivity to any of the components of Eprex.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 副作用     | Increased BP, thrombotic or vascular events. Flu-like symptoms, bone pain & chills after inj. Seizures. Skin reactions, palpebral edema. Rarely, erythroblastopenia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 孕期建議   | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 哺乳期建議 | Contraindicated 哺乳期使用禁忌                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

